113 related articles for article (PubMed ID: 12569299)
1. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Zhai S; Sausville EA; Senderowicz AM; Ando Y; Headlee D; Messmann RA; Arbuck S; Murgo AJ; Melillo G; Fuse E; Figg WD
Anticancer Drugs; 2003 Feb; 14(2):125-35. PubMed ID: 12569299
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
Rudek MA; Bauer KS; Lush RM; Stinson SF; Senderowicz AM; Headlee DJ; Arbuck SG; Cox MC; Murgo AJ; Sausville EA; Figg WD
Ann Pharmacother; 2003 Oct; 37(10):1369-74. PubMed ID: 14519054
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
7. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA
PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
Blum W; Phelps MA; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM; Johnson A; Schaaf LJ; Byrd JC; Marcucci G; Grever MR
Haematologica; 2010 Jul; 95(7):1098-105. PubMed ID: 20460644
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter.
Hsieh TY; Shiu TY; Huang SM; Lin HH; Lee TC; Chen PJ; Chu HC; Chang WK; Jeng KS; Lai MM; Chao YC
Pharmacogenet Genomics; 2007 Apr; 17(4):229-36. PubMed ID: 17496722
[TBL] [Abstract][Full Text] [Related]
12. Single-step identification of all length polymorphisms in the UGT1A1 gene promoter.
Skarke C; Grösch S; Geisslinger G; Lötsch J
Int J Clin Pharmacol Ther; 2004 Mar; 42(3):133-8. PubMed ID: 15049432
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Shapiro GI; Supko JG; Patterson A; Lynch C; Lucca J; Zacarola PF; Muzikansky A; Wright JJ; Lynch TJ; Rollins BJ
Clin Cancer Res; 2001 Jun; 7(6):1590-9. PubMed ID: 11410495
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
Innocenti F; Stadler WM; Iyer L; Ramírez J; Vokes EE; Ratain MJ
Clin Cancer Res; 2000 Sep; 6(9):3400-5. PubMed ID: 10999721
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
Schwartz GK; O'Reilly E; Ilson D; Saltz L; Sharma S; Tong W; Maslak P; Stoltz M; Eden L; Perkins P; Endres S; Barazzoul J; Spriggs D; Kelsen D
J Clin Oncol; 2002 Apr; 20(8):2157-70. PubMed ID: 11956278
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.
George S; Kasimis BS; Cogswell J; Schwarzenberger P; Shapiro GI; Fidias P; Bukowski RM
Clin Lung Cancer; 2008 May; 9(3):160-5. PubMed ID: 18621626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
